Akèy › Leksemi mieloïd egi › Wisconsin › Milwaukee
Etid klinik pou Leksemi mieloïd egi nan Milwaukee, WI
17 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Milwaukee (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- ak 9 plis
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Children's Hospital of Wisconsin, Milwaukee
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Aurora Cancer Care-Milwaukee, Milwaukee
- Aurora Saint Luke's Medical Center, Milwaukee
- Medical College of Wisconsin, Milwaukee
- ak 12 plis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Medical College of Wisconsin, Milwaukee
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Children's Hospital of Wisconsin, Milwaukee
A Study of BGB-11417 in Participants With Myeloid Malignancies
Ap rekriteFaz 1/2
- Medical College of Wisconsin, Milwaukee
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Froedtert & Medical College of Wisconsin, Milwaukee
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Froedtert & Medical College Clinics, Milwaukee
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Ap rekriteFaz 1
- Medical College of Wisconsin, Milwaukee
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- Children's Hospital of Wisconsin, Milwaukee
Ivosidenib as Post-HSCT Maintenance for AML
Ap rekriteFaz 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Ap rekriteFaz 2/3
- Froedtert & Medical College of Wisconsin, Milwaukee
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- Medical College of Wisconsin Cancer Center, Milwaukee
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Ap rekriteFaz 1
- Children's Wisconsin, Milwaukee
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Baldwin Park, CA40 etid
- Seattle, WA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA30 etid
- Tampa, FL29 etid
- Chicago, IL26 etid
- Portland, OR25 etid
Lòt etid nan Milwaukee
- Kansè nan tete23 etid
- Kansè Poumon ki pa ti selil22 etid
- Kansè (tout kalite)22 etid
- Kansè poumon21 etid
- Myelom Miltip21 etid
- Kansè pwostat20 etid
- Limfòm folikilè19 etid
- Kansè pankreyas18 etid
- Limfòm Non-Hodgkin18 etid
- Kansè ovè17 etid
- Limfòm Burkitt16 etid
- Ensifizyans kadyak16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.